Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Greg D. Carmichael received an equity award of 1,634 shares of Encompass Health Common Stock. The shares were granted on 2026-05-07 as an annual grant of restricted stock units under the Corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, Carmichael directly holds 20,320 shares of Encompass Health Common Stock.
Williams Terrance reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Terrance Williams received an equity grant of 1,634 shares of Encompass Health Common Stock. The shares were awarded at no cash cost as an annual grant of restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan, bringing his direct holdings to 16,830 shares.
KATZ LESLYE G reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Leslye G. Katz received an annual grant of 1,634 shares of Encompass Health Common Stock on May 7, 2026. The award was granted at no cash cost as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan.
Following this grant, Katz directly holds 49,558 shares of Encompass Health Common Stock. This is a routine equity compensation award rather than an open-market purchase or sale, so it does not reflect a discretionary trading decision in the company’s stock.
HERMAN JOAN E reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Joan E. Herman received a grant of 1,634 Encompass Health common shares as a compensation award. The shares were granted at no cash cost to Herman as part of an annual restricted stock unit award under the corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, Herman directly holds 49,558 shares of Encompass Health common stock. This is a routine equity compensation grant rather than an open-market purchase or sale.
SCHLICHTING NANCY M reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Nancy M. Schlichting received an annual grant of 1,634 restricted stock units of Encompass Health Common Stock at no cost under the corporation's 2025 Omnibus Performance Incentive Plan. Following this grant, she directly holds 22,932 shares of Encompass Health Common Stock.
Encompass Health Corporation reported strong first-quarter 2026 growth, with net operating revenues of $1,586.6 million, up 9.0% from $1,455.4 million a year earlier, driven by higher patient volumes and improved pricing.
Net income attributable to Encompass Health rose to $194.5 million from $151.5 million, and diluted EPS increased to $1.93 from $1.48. Adjusted EBITDA reached $348.8 million versus $313.6 million. Cash from operating activities was $313.1 million, supporting continued hospital expansion, dividends, and share repurchases while managing long-term debt maturities beginning in 2028.
Encompass Health Corporation reported strong first-quarter 2026 results and raised its full-year outlook. Net operating revenue grew 9.0% to $1,586.6 million, driven by 4.3% higher discharges and a 3.7% increase in net patient revenue per discharge to $22,633.
Adjusted EBITDA rose 11.2% to $348.8 million, while diluted earnings per share from continuing operations increased to $1.77, with adjusted earnings per share up 16.8% to $1.60. Adjusted free cash flow was $193.8 million, down from $222.4 million a year earlier, reflecting higher maintenance capital spending and distributions to noncontrolling interests.
The company continued to expand capacity, opening a new 49-bed hospital in Irmo, South Carolina and adding 44 beds at existing facilities. It amended and restated its credit agreement, extending maturity to March 2031, and reported net leverage of 1.9x. Encompass Health repurchased 707,965 shares for $71.6 million and paid a quarterly dividend of $0.19 per share.
For full-year 2026, management modestly increased guidance, now expecting net operating revenue of $6,375 million to $6,470 million, Adjusted EBITDA of $1,350 million to $1,380 million, and adjusted earnings per share from continuing operations of $5.89 to $6.11.
Encompass Health Corp reports beneficial ownership of 5,233,622 shares of Common Stock, representing 5.26% of the class as of 03/31/2026. The filing attributes sole voting power for 767,385 shares and sole dispositive power over 5,233,622 shares to Vanguard Capital Management and certain affiliates under SEC Release No. 34-39538.
Encompass Health Corp passive ownership disclosure: Vanguard Portfolio Management reported beneficial ownership of 4,971,601 shares, representing 5% of common stock.
The filing states Vanguard has sole voting power for 12,056 shares and sole dispositive power for 4,971,601 shares. The report is signed by Ashley Grim on 04/29/2026.
CARMICHAEL GREG D reported acquisition or exercise transactions in this Form 4 filing.
Encompass Health Corp director Greg D. Carmichael received additional stock-based compensation through a routine dividend-related award. On April 15, 2026, he was granted 27 restricted stock units (RSUs) of Encompass Health Common Stock at no cash cost, increasing his direct holdings to 18,686 shares.
The footnote explains that, under outstanding RSU award agreements, extra RSUs are credited to each non-employee director when common stock dividends are paid. The number of RSUs is based on the existing RSU balance, the per share dividend of $0.19, and the $105.24 closing price on the dividend payment date.